Cargando…

Oncofetal markers CA 19-9, CA 125 and SP1 in healthy children and in children with malignancy.

Detalles Bibliográficos
Autores principales:	Heikinheimo, M., Rajantie, J., Kuusela, P., Kallio, M. J., Siimes, M. A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971508/ https://www.ncbi.nlm.nih.gov/pubmed/2245182

Ejemplares similares

Oncological markers CA-125, CA 19-9 and endometriosis
por: Fiala, Ludek, et al.
Publicado: (2018)

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.
por: Haglund, C., et al.
Publicado: (1989)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
por: Haglund, C., et al.
Publicado: (1986)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

Tenascin and oncofetal fibronectin--oncofetal markers or indicators of extracellular matrix remodelling?
por: David, L.
Publicado: (1996)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis
por: Tascı, Canturk, et al.
Publicado: (2012)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

Comparison of Ultrasound and Tumor Marker CA125 in Diagnosis of Adnexal Mass Malignancies
por: Behnamfar, Fariba, et al.
Publicado: (2022)

Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge
por: Zhao, Song, et al.
Publicado: (2016)

Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies
por: Schröder, Lars, et al.
Publicado: (2023)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

CA-125 is not a useful marker in metastatic breast cancer.
por: Seckl, M. J., et al.
Publicado: (1992)

Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer
por: Ali, Fahmy T., et al.
Publicado: (2022)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma
por: Isaksson, Sofi, et al.
Publicado: (2017)

The Diagnostic Accuracy of Combined Enolase/Cr, CA125, and CA19-9 in the Detection of Endometriosis
por: Rokhgireh, Samaneh, et al.
Publicado: (2020)

Clinical significance of serum CA125 in diffuse malignant mesothelioma
por: Cheng, Xu, et al.
Publicado: (2016)

Exploring the Glycosylation of Serum CA125
por: Saldova, Radka, et al.
Publicado: (2013)

Peritoneal trauma releases CA125?
por: Redman, C. W., et al.
Publicado: (1988)

Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer
por: Gao, Yanfeng, et al.
Publicado: (2018)

Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
por: Sun, Zhipeng, et al.
Publicado: (2014)

A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion
por: Hogendorf, Piotr, et al.
Publicado: (2017)

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
por: Sánchez Vega, Juan Fernando, et al.
Publicado: (2018)

Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
por: Feng, Fan, et al.
Publicado: (2017)

CA125 effects on humoral immunosuppression
por: Kline, J. Bradford, et al.
Publicado: (2017)

An Antibody‐Tumor Model for the Targeting of CA125‐producing Gynecologic Malignancies
por: Saga, Tsuneo, et al.
Publicado: (1990)

Clinical significance and diagnostic value of serum NSE, CEA, CA19-9, CA125 and CA242 levels in colorectal cancer
por: Luo, Hai, et al.
Publicado: (2020)

CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies
por: Deng, Lin, et al.
Publicado: (2020)

Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression
por: Foda, Abd AlRahman Mohammad, et al.
Publicado: (2023)

Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative
por: Dunton, Charles J., et al.
Publicado: (2021)

Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma
por: Hu, Hai-Jie, et al.
Publicado: (2016)

Significant elevation in serum CA 125 and CA 19-9 levels with torsion of the hydrosalpinx in a postmenopausal woman
por: Kim, Ji Hye, et al.
Publicado: (2017)

Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
por: Fang, Tianyi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0blasuvacqr9tvqo0qss24k8mf